Early Alert: Medline ReNewal Reprocessed EP Catheters with Residual Particulates – What You Need to Know

Date of FDA Page Update: August 6, 2025 U.S. Food and Drug Administration

The device and product details

• Products involved:
  • Reprocessed St. Jude Medical Response Diagnostic Electrophysiology Catheter
  • Supreme Electrophysiology Catheter
  • Affected lots: EP241118 and EP250106 U.S. Food and Drug Administration

These catheters are used for electrophysiology (EP) mapping, stimulation, and recording in diagnosing and managing cardiac arrhythmias via endocardial and intravascular access. U.S. Food and Drug Administration

Reason for the Early Alert

Medline ReNewal found that affected lots may contain small residual particulates on patient-contacting surfaces. If introduced into the bloodstream, these particulates may trigger dangerous reactions—including:

• Inflammatory responses or systemic infections
• Granulomatous reactions or thrombus formation
• Cerebral or pulmonary embolism
• Deep vein thrombosis U.S. Food and Drug Administration

No serious injuries or deaths have been reported as of July 29, 2025—but the risk is high due to the device’s invasive use. U.S. Food and Drug Administration

---

What the FDA is Doing

This communication is part of FDA’s Communications Pilot to Enhance the Medical Device Recall Program. The FDA:

• Issued a public Early Alert to raise awareness quickly
• Is actively reviewing information and potentially higher-risk signals
• Will update the public as significant information becomes available U.S. Food and Drug Administration

This is not yet a formal recall; the alert enables stakeholders to act preemptively while FDA analysis continues.

---

What Healthcare Providers and Facilities Should Do Now

1. Inventory check & quarantine
   • Search your records and physical inventory for the specified lots (EP241118, EP250106)
   • Quarantine all identified units immediately U.S. Food and Drug Administration
2. Notify downstream users
   • If you distributed or transferred these devices, you must notify those recipients and ask them to do the same. U.S. Food and Drug Administration
3. Return process
   • Medline ReNewal sent customers a “Dear Customer” letter (on July 14) with a response form
   • Fill out the quantity you hold (even if zero), return it, and await return labels/RGA information for shipment and credit U.S. Food and Drug Administration
4. Monitoring and reporting
   • Report any adverse events or quality issues tied to these devices via FDA’s MedWatch system U.S. Food and Drug Administration

---

Manufacturer Responsibilities — What Medline ReNewal Must Do

1. Confirm and Contain

• Validate and confirm the scope of affected lots and devices.
• Coordinate quarantine and logistics to recover all impacted units globally.

2. Analyze Root Cause

• Investigate where particulate contamination occurred—whether during reuse processing, cleaning, sterilization, or packaging.
• Perform failure analysis and recall validation (e.g., examine cleaning logs, reprocessing equipment, procedural compliance).

3. Corrective Actions

• Revise reprocessing protocols (cleaning, inspection, sterilization, final cleaning validation).
• Apply enhanced inspection procedures (e.g., microscopic or visual checks for cleanliness).
• Implement new QA checkpoints and process validations to catch minute particulates before distribution.

4. Regulatory Coordination

• Immediately update FDA and other regulators (e.g., EU Notified Bodies) with corrective action plans.
• If formal recall becomes necessary, prepare recall documentation, root cause reports, and mitigation strategies.

5. Stakeholder Communication

• Send updated Dear Customer notifications with precise cleaning, examination steps, and expected timelines for return and replacement.
• Create FAQs, training materials, and customer service scripts to ensure frontline teams can reliably advise clinicians and facilities.

6. Quality System Update

• Amend SOPs, DHF (Design History File), and QMS documentation to reflect updated reprocessing methodologies.
• Document the CAPA (Corrective and Preventive Actions) activities and complete effectiveness validations.

7. Postmarket Surveillance

• Intensify surveillance for similar events in non-affected lots.
• Monitor for any complications potentially tied to particulate contamination.

---

Summary Table

Stakeholder	Immediate Actions
FDA	Posted early alert, reviewing data.
Medline ReNewal	Quarantine, root-cause investigation, implement corrective actions, communicate.
Healthcare Providers & Distributors	Quarantine units, return to Medline, report issues.
Patients	N/A (no direct patient action unless notified by clinician).

---

Why This Alert Matters

The presence of residual particulates on EP catheters—which are inserted directly into the heart and bloodstream—poses a serious risk of embolism, infection, or inflammation. Even absent injuries, the potential for catastrophic harm justifies this swift, public safety measure. It underscores the need for watertight reprocessing protocols in reprocessed medical devices.

Contact us: company@shudarsana.com